ex vivo expanded peripheral blood mononuclear cells

Ex vivo expanded peripheral blood mononuclear cells (EVE PBMNC) is an autologous cell therapy investigated for its potential to accelerate hematological recovery and prevent neutropenia in patients undergoing high-dose chemotherapy for relapsed or refractory non-Hodgkin's lymphoma. The therapy involves harvesting mononuclear cells from the patient's own peripheral blood, which are then cultured and expanded ex vivo for approximately 13 days. This expansion process utilize a cocktail of cytokines and growth factors, specifically flt3 ligand, interleukin-3 (IL-3), filgrastim (G-CSF), sargramostim (GM-CSF), and epoetin alfa (EPO), to stimulate the proliferation and maturation of hematopoietic progenitor cells. Once expanded, the cells are reinfused into the patient to supplement a conventional autograft, providing a larger population of precursor cells to rapidly reconstitute white blood cells, red blood cells, and platelets.

Other names

expanded peripheral blood mononuclear cellsautologous expanded PBMNCexpanded PBMNC